Skip to main content
SpringerLink
Log in

Expressions of CD147, MMP-2 and MMP-9 in Laryngeal Carcinoma and its Correlation with Poor Prognosis

Pathology & Oncology Research

Abstract

The objectives of this study are to investigate the expressions of matrix metalloproteinase inducing factor (CD147), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) in laryngeal tumor tissues and its significant correlation with tumor infiltration, metastasis and prognosis. Laryngeal tumor tissue from 48 laryngeal cancer patients with complete clinical information was collected. The laryngitis tissue from 15 patients were collected as control group. Immunohistochemical analysis for CD147, MMP-2 and MMP-9 was performed for all the tissue. The results showed the expression rates of CD147, MMP-2 and MMP-9 in laryngeal carcinoma were 87.5 %, 75.0 % and 79.2 % respectively, significantly higher than those (26.7 %, 6.7 %, and 33.3 % respectively) in the control group are (P < 0.01). High expression of CD147, MMP-2 and MMP-9 related to the clinical stages and lymphatic metastasis of laryngeal carcinoma. Univariate survival analysis showed that the 5-year survival of laryngeal carcinoma patients with low expression of CD147, MMP-2 and MMP-9was 83.3 %, 83.3 % and 90 % respectively, while the patients with high expression had 5-year survival at 25 %, 7.7 % and 18.2 % respectively (P < 0.05). Multiple regression analysis showed that high expression of MMP-9 was independently associated with poor prognosis (P < 0.05). High expression of CD147, MMP-2 and MMP-9 were related with laryngeal carcinoma invasion and metastasis. High expressions of CD147, MMP-2 and MMP-9 were all predictive factors of poor prognosis of laryngeal carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M (2006) Emmprin (basigin/CD147):matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56:359–367

    Article  CAS  PubMed  Google Scholar 

  2. Tang Y, Kesavan P, Nakada MT, Yan L (2004) Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol Cancer Res 2:73–80

    CAS  PubMed  Google Scholar 

  3. Kato Y, Yamashita T, Ishikawa M (2002) Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 9:565–569

    CAS  PubMed  Google Scholar 

  4. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  CAS  PubMed  Google Scholar 

  5. Jodele S, Blavier L, Yoon JM, DeClerk YA (2006) Modifying the soil to affect the seed: Role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 25:35–43

    Article  CAS  PubMed  Google Scholar 

  6. Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L, Zhang Y, Liao CG, Bian HJ, Jiang JL, Yang XM, Li XY, Fan CM, Zhu P, Fu L, Chen ZN (2009) HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection. Histopathology 54:677–687

    Article  CAS  PubMed  Google Scholar 

  7. Guo H, Li R, Zucker S, Toole BP (2000) EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 60:888–891

    CAS  PubMed  Google Scholar 

  8. Riethdorf S, Reimers N, Assmann V, Kornfeld JW, Terracciano L, Sauter G, Pantel K (2006) High incidence of EMMPRIN expression in human tumors. Int J Cancer 119:1800–1810

    Article  CAS  PubMed  Google Scholar 

  9. Noguchi Y, Sato T, Hirata M, Hara T, Ohama K, Ito A (2003) Identification and characterization of extracellular matrix metalloproteinase inducer in humane ndometrium during the menstrual cycle in vivo and in vitro. J Clin Endocrinol Metab 88:6063–6072

    Article  CAS  PubMed  Google Scholar 

  10. Kanekura T, Chen X, Kanzaki T (2002) Basigin (CD147)is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 99:520–528

    Article  CAS  PubMed  Google Scholar 

  11. Xu J, Shen ZY, Chen XG, Zhang Q, Bian HJ, Zhu P, Xu HY, Song F, Yang XM, Mi L, Zhao QC, Tian R, Feng Q, Zhang SH, Li Y, Jiang JL, Li L, Yu XL, Zhang Z, Chen ZN (2007) A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 45:269–276

    Article  CAS  PubMed  Google Scholar 

  12. Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down regulating glycolysis. Cancer Lett 273:140–147

    Article  CAS  PubMed  Google Scholar 

  13. Kuang YH, Chen X, Su J, Wu LS, Li J, Chang J, Qiu Y, Chen ZS, Kanekura T (2008) Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J Proteome Res 7:4784–4791

    Article  CAS  PubMed  Google Scholar 

  14. Jia L, Wei W, Cao J, Xu H, Miao J, Zhang J (2009) Silencing CD147 inhibits tumor progression and increases chemosensitivity inmurine lymphoid neoplasm P388D1 cells. Ann Hematol 88(8):753–760

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The study is supported by Health Commission Funding for Science and Technology Talent.

Conflict of interest

There is no conflict of interests between the authors.

Author information

Authors and Affiliations

  1. Department of Oncology, Guizhou Cancer Hospital, The Affiliated Hospital of Guiyang Medical College, Guiyang, 550003, China

    Xiaoxia Gou, Haixia Chen, Feng Jin, Weili Wu, Yuanyuan Li, Jinhua Long, Xiuyun Gong, Mengyalan Luo, Ting Bi, Zhuolin Li & Qianyong He

  2. Department of Oncology, The Affiliated Hospital of Zunyi Medical College, Zunyi, 553003, China

    Xiaoxia Gou

Authors
  1. Xiaoxia Gou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haixia Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Feng Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weili Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuanyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jinhua Long
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiuyun Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mengyalan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ting Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhuolin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qianyong He
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Feng Jin.

Additional information

Xiaoxia Gou and Haixia Chen contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gou, X., Chen, H., Jin, F. et al. Expressions of CD147, MMP-2 and MMP-9 in Laryngeal Carcinoma and its Correlation with Poor Prognosis. Pathol. Oncol. Res. 20, 475–481 (2014). https://doi.org/10.1007/s12253-013-9720-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9720-3

Keywords

Search

Navigation